Search Results

Rylie Chambers, MSN, AGPCNP-BC, OCN, is a board-certified Adult-Geriatric Primary Care Nurse Practitioner with a specialization in oncology. She graduated magna cum laude from Indiana University of Pennsylvania earning her Bachelor of Science in Nursing and recognition as a provost scholar from her accredited nursing program. Rylie went on to complete her Master of Science…

Whether you were diagnosed with cervical cancer following routine screening or after experiencing symptoms, deciding what to do next can feel overwhelming. The right treatment for you may depend on a variety of factors, including the type and stage of your cervical cancer, any potential side effects, and your personal preferences. While there’s a lot…

Human papillomavirus (HPV) is a sexually transmitted infection that is spread through intimate, skin-to-skin contact. HPV comprises a group of more than 150 related viruses that thrive in the cells found on the skin’s surface or other moist (mucosal) surfaces. Some HPV types cause common skin warts or low-risk genital warts. Other HPV types are…

An Interventional Phase 3, Double-Blind, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer MOA: PF-08634404 is a PD-1xVEGF bispecific antibody. Key Eligibility Criteria: LA (Stage IIIB/C) or met (Stage IV) squamous or…

A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer MOA: Pumitamig (BMS-986545/BNT327) is a bispecific antibody targeting PD-L1 and VEG-F. Key Eligibility Criteria: Previously untreated, histologically confirmed recurrent or metastatic colorectal adenocarcinoma, not amenable to curative…

A randomized, Phase 3, open-label study to evaluate PF-08046054/SGN-PDL1V vs Docetaxel in adult participants with previously-treated programmed cell death ligand (PD-L1) positive non-small cell lung cancer (NSCLC) MOA: PF-08046054/SGN-PDL1V is an anti-PD-L1 ADC with a MMAE payload Key Eligibility Criteria: Histologically or cytologically documented unresectable Stage IIIB, IIIC, IV NSCLC not eligible for definitive chemoradiotherapy.…